Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avandia Safety Under The Microscope

This article was originally published in The Pink Sheet Daily

Executive Summary

Cardiovascular risks identified in a meta-analysis by Steven Nissen prompt immediate announcements of an advisory committee meeting and congressional investigations.
Advertisement

Related Content

Avandia Day Two Might Be Same Old Song Even With Broken RECORD
Industry Pays Fees, FDA Should Deliver, Nissen Says Of Missed PDUFA Dates
Industry Pays The Fees, FDA Should Deliver, Nissen Says Of Missed PDUFA Dates
Prime Will Delete Avandia From Medicare Formulary, Urging Blues Members To Follow Suit
Avandia Retains Preferred Status In Part D Formularies For 2008
Avandia and Actos Add Strengthened “Black Box” Warnings On Heart Failure
Avandia Should Stay On Market, Committee Says
Avandia’s Fate May Hang On How Advisory Cmte. Weighs Meta-Analyses Vs. Other Data
Takeda Halts Development Of Actos Combination Product
Drug Safety Expected To Be Only Addition To PDUFA Reauthorization In House

Topics

Advertisement
UsernamePublicRestriction

Register

PS066064

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel